GRI Bio (GRI) to Release Quarterly Earnings on Tuesday

GRI Bio (NASDAQ:GRI) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($1.31) per share for the quarter.

GRI Bio (NASDAQ:GRI) last posted its earnings results on Thursday, May 15th. The company reported ($5.80) earnings per share for the quarter, missing the consensus estimate of ($4.08) by ($1.72). On average, analysts expect GRI Bio to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

GRI Bio Trading Up 0.8%

Shares of GRI Bio stock opened at $1.26 on Friday. GRI Bio has a twelve month low of $1.10 and a twelve month high of $30.43. The stock has a market cap of $3.15 million, a price-to-earnings ratio of -0.11 and a beta of -1.61. The company has a fifty day moving average price of $1.53 and a 200 day moving average price of $3.67.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Ascendiant Capital Markets decreased their target price on GRI Bio from $40.00 to $34.00 and set a “buy” rating for the company in a research report on Tuesday, May 27th. HC Wainwright restated a “buy” rating on shares of GRI Bio in a report on Wednesday, June 11th.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.